PATENT CLAIM ANALYSIS

Application Number: 16025199
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-10
Patent Classification: ["514", "364000"]

Abstract:
This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Claim (Index 4):
The composition according to  claim 3 , wherein said compound is: Compound Number Structure \u20026   27   28   29   35   36   37   38   39   40   42   43   46   47   48   49   50   51   53

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.27273
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15151740', '13458452', '14628373', '15123791', '15866871']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7683148218494493
- 35 USC 102 Novelty (BERT): 0.5418911376622917
- Combined Prediction Score: 0.7456724534307335
- Mean Citation Score: 313.2950019999999
- Max Citation Score: 365.27896
- Similarity Product: 229.81868799181456

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test